PER® Chemotherapy Foundation Symposium (CFS) | Conference

Efforts Continue to Perfect PARPi Use in Ovarian Cancer

November 8th 2019

As PARP inhibitors have now moved into the frontline maintenance setting in ovarian cancer, researchers are now seeking to even further capitalize on use of these agents, including indications in treatment-naïve patients.

Adjuvant Immunotherapy Combinations on Horizon for Melanoma

November 8th 2019

Quickly following on the approval of single agents, adjuvant immunotherapy combinations are quickly progressing through development, with promising signs of clinical activity seen in phase II studies, according to a presentation by Jeffrey S. Weber, MD, PhD, at the 37th Annual CFS®.

Dr. Furman on Prognostic Markers in High-Risk CLL

November 7th 2019

Richard R. Furman, MD, discusses the role of prognostic markers in high-risk chronic lymphocytic leukemia.

Dr. Motzer on First-Line Treatment of Metastatic RCC

November 7th 2019

Robert J. Motzer, MD, discusses the first-line treatment landscape of metastatic clear cell renal cell carcinoma.

Novel Combinations Could Improve Cure Rates for Adult ALL

November 7th 2019

Novel combinations of biologic therapies, third-generation TKIs, and chemotherapy could lead to significantly higher cure rates for adult patients with acute lymphoblastic leukemia, with a number of early stage studies already showing promising results, according to Hagop M. Kantarjian, MD, at the 37th Annual CFS®.

Expert Explains Treatment Considerations in Newly Diagnosed Follicular Lymphoma

November 7th 2019

Given that a watch-and-wait approach is a viable option, clinicians must carefully consider disease characteristics when selecting a treatment strategy in newly diagnosed follicular lymphoma.

Anti-BCMA Approaches Ascending in Multiple Myeloma

November 7th 2019

Anti-BCMA directed treatments, including CAR T-cell therapy, bispecific antibodies, and antibody-drug conjugates, have the potential to revolutionize the multiple myeloma treatment paradigm. At the 37 Annual CFS®, Sham Mailankody, MBBS, discussed the emerging BCMA-directed therapies that have shown the greatest potential.

Immunotherapy Approval Offers New Hope in CSCC

November 9th 2018

Treatment for cutaneous squamous cell carcinoma (CSCC) took a great leap forward in September 2018 with the PD-1 inhibitor cemiplimab becoming the first agent specifically approved by the FDA for advanced CSCC.

Adjuvant Options Arrive for Melanoma

November 9th 2018

The treatment armamentarium for adjuvant melanoma has expanded rapidly, which has left the treatment challenge of selecting between immunotherapy and targeted therapy without any head-to-head comparative data.

Personalized Immunotherapy Combinations on Horizon

November 9th 2018

Future development of novel immunotherapy combinations should be based on individual patient characteristics, such as patient-level immune targets and tumor microenvironment.

Emerging Agents, Strategies Propel Progress in Follicular Lymphoma

November 8th 2018

Novel agents and treatment strategies continue to expand the armamentarium in follicular lymphoma, explains John P. Leonard, MD, in a session at the 36th Annual CFS®.

CAR T-Cell Therapies Moving to Outpatient Setting

November 8th 2018

The high durable response rates seen with CAR T-cell therapies have helped fill a high unmet need for patients with relapsed/refractory diffuse large B-cell lymphoma, with questions remaining on the optimal way to use these agents following the FDA approval of 2 therapies in the past year.

Novel Agents, Earlier Diagnosis Driving Survival Gains in CLL

November 8th 2018

The median overall survival for patients with chronic lymphocytic leukemia has more than tripled since the 1970s, primarily due to an ever-expanding armamentarium of novel agents and earlier diagnosis.

Dr. Markman on Endpoints in Clinical Trials for Ovarian Cancer

November 16th 2017

Maurie Markman, MD, president of medicine and science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses endpoints in clinical trials for ovarian cancer.

Dr. Bendell on the Future of Regorafenib for Patients With CRC

November 15th 2017

Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses the future of regorafenib (Stivarga) for patients with colorectal cancer (CRC).

Expert Discusses Treatment Options in Advanced CRC

November 13th 2017

Cathy Eng, MD, discusses optimizing sequencing beyond disease progression in CRC.

Comparing Abiraterone and Docetaxel in Prostate Cancer Treatment

November 11th 2017

Christopher Sweeney, MBBS, physician, Dana-Farber Cancer Institute, compares treatment with abiraterone verus docetaxel in patients with prostate cancer.

EGFR-Positive NSCLC Is Emerging as Model for Precision Medicine

November 11th 2017

It has been a “renaissance” in the non–small cell lung cancer landscape with the rapid evolution of targeted treatment for patients with EGFR-mutation–positive disease, says Edward S. Kim, MD.

Dr. Garon on Immunotherapy as Salvage Treatment for Advanced Lung Cancer

November 11th 2017

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at UCLA, discusses the possibility of administering PD1 or PD-L1 blockades as a third-line or salvage therapy for patients with advanced lung cancer.

Treating Advanced Non-Driver Lung Adenocarcinoma

November 11th 2017

The approach to first-line treatment of advanced non-small cell lung cancer (NSCLC) has been evolving rapidly, particularly with respect to patients with lung adenocarcinoma.